Inhibrx Reports Fourth Quarter and Fiscal Year 2025 Financial Results

Inhibrx Inc (NASDAQ:INBX) has reported its financial results for the fourth quarter and fiscal year 2025, revealing a net loss of USD 24.5 million for the quarter, which translates to a loss of USD 0.82 per share. This marks a significant increase in losses compared to the same quarter in the previous year, where the net loss was USD 18.3 million, or USD 0.61 per share. The company's total revenue for the fiscal year 2025 was USD 12 million, primarily driven by its ongoing clinical trials and collaborations, which is a notable increase from USD 8 million in fiscal year 2024. The increase in revenue reflects the company's strategic focus on advancing its pipeline of therapeutic candidates, including INBRX-101 and INBRX-105, which are currently in various stages of clinical development.

The announcement comes at a critical juncture for Inhibrx, as it continues to navigate the complexities of the biotechnology sector, particularly in the development of innovative therapies for cancer and autoimmune diseases. The company ended the fiscal year with cash and cash equivalents of USD 85 million, which management indicates is sufficient to fund operations into the second half of 2026. This financial cushion is crucial as Inhibrx prepares for upcoming clinical trial milestones and potential regulatory submissions. However, the significant increase in losses raises concerns about the sustainability of its current operational model, especially if revenue growth does not accelerate in line with expectations.

In terms of valuation, Inhibrx's current market capitalisation stands at approximately USD 1.93 billion, based on its share price of USD 64.87. When compared to its peers in the biotechnology sector, such as Amgen Inc (NASDAQ:AMGN) and Regeneron Pharmaceuticals Inc (NASDAQ:REGN), Inhibrx appears to be trading at a premium. Amgen, with a market cap of around USD 134 billion, has an EV/EBITDA ratio of approximately 15.5, while Regeneron, valued at about USD 66 billion, has an EV/EBITDA ratio of around 12.5. Inhibrx, on the other hand, is currently valued at an EV/EBITDA ratio that suggests a higher growth expectation, given its early-stage pipeline and the potential for significant upside if its clinical trials yield positive results.

The funding runway for Inhibrx appears solid, with its current cash position providing a buffer against immediate dilution risks. However, the company may need to consider additional financing options in the future to support its ambitious development plans, particularly if clinical trials require more extensive funding than currently anticipated. The potential for dilution exists if the company opts for equity financing, especially if the share price does not appreciate significantly in the near term.

Historically, Inhibrx has demonstrated a commitment to meeting its clinical milestones, although the recent increase in losses could indicate challenges in managing operational costs effectively. The company has previously met its timelines for initiating clinical trials, but the pressure to deliver results will intensify as investors look for evidence of progress in its drug development pipeline. Specific risks highlighted by this announcement include the potential for delays in clinical trials, which could impact the timeline for revenue generation and further funding requirements.

Looking ahead, the next significant catalyst for Inhibrx is the anticipated data readout from its ongoing Phase 2 clinical trial of INBRX-101, expected in mid-2026. This trial is critical as it will provide insights into the efficacy of the therapy and could influence the company's strategic direction and funding needs moving forward. The results from this trial will be pivotal not only for Inhibrx's valuation but also for its ability to attract further investment and partnerships.

In summary, while Inhibrx's fourth quarter and fiscal year 2025 results reflect a growing revenue base and a solid cash position, the increasing net losses raise questions about its operational efficiency and long-term sustainability. The company's current valuation appears elevated compared to its peers, reflecting high growth expectations that will need to be met through successful clinical outcomes. The announcement is classified as significant, given its implications for future funding, operational strategy, and the critical milestones that lie ahead for the company.

Key insights

• ●Inhibrx's Q4 loss increased to USD 24.5 million.
• ●Total revenue for FY 2025 reached USD 12 million.
• ●Next catalyst: Phase 2 trial data for INBRX-101 expected mid-2026.

Disagree with this article?